Progyny, Inc. (NASDAQ:PGNY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Progyny, Inc. has received a consensus recommendation of “Moderate Buy” from ten analysts, with an average price target of $25.44.
• The company reported $0.19 EPS in its last quarterly earnings, missing analyst estimates of $0.42, though revenue exceeded estimates at $332.87 million.
• Recent insider trading includes sales by EVP Allison Swartz and Director Kevin K. Gordon, indicating a decrease in their stock ownership.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $25.4444.

A number of equities research analysts have recently commented on PGNY shares. Raymond James Financial set a $28.00 price target on shares of Progyny in a report on Friday, August 8th. Weiss Ratings restated a "hold (c-)" rating on shares of Progyny in a research report on Saturday, September 27th. Leerink Partnrs upgraded Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 8th. JPMorgan Chase & Co. raised their price objective on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th.

Progyny Stock Performance

Progyny stock opened at $20.59 on Monday. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $26.76. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 1.75 and a beta of 1.34. The stock has a fifty day moving average of $22.59 and a two-hundred day moving average of $22.26.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). The company had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm's revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Insider Transactions at Progyny

In related news, EVP Allison Swartz sold 2,398 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director directly owned 12,501 shares of the company's stock, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,895 shares of company stock valued at $179,311. Corporate insiders own 9.40% of the company's stock.

Institutional Trading of Progyny

Several institutional investors have recently made changes to their positions in PGNY. Cetera Trust Company N.A raised its position in shares of Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company's stock worth $29,000 after buying an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Progyny during the first quarter worth about $44,000. Militia Capital Partners LP raised its holdings in shares of Progyny by 100.0% in the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock worth $45,000 after purchasing an additional 1,000 shares during the period. Brooklyn Investment Group lifted its stake in shares of Progyny by 5,216.4% in the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after purchasing an additional 3,182 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Progyny during the 2nd quarter worth about $77,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.